
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 13, 2026, 7:00 AM ET
BioCryst presents real-world data at ACAAI 2026 showing a 30% decrease in angioedema-related visits after switching to ORLADEYO.
Nasdaq: $BCRXHereditary angioedemaProfitable on ORLADEYONavenibart topline Q3 2027Book equity negative after the Astria deal
BCRX Stock Hub: BioCryst News, ORLADEYO and Navenibart
BioCryst earned an operating profit of $53.3 million in the September quarter on $180.3 million of revenue, of which ORLADEYO contributed $174.8 million, and raised its full-year total revenue guidance to $715–730 million. The same nine months show a $605.5 million net loss, because the $874.3 million acquisition of Astria Therapeutics put $697.8 million of acquired in-process research and development through the income statement, and the company now carries $988.5 million of liabilities against $591.1 million of assets. Both things are true at once, and the difference is the whole story.
Full research report · PDF
BioCryst Pharmaceuticals ($BCRX) research updated November 18, 2026
14 pages: the ORLADEYO franchise and the pellet approval, the CareMed pharmacy transition and the inventory effect, the September quarter and the guidance, the Blackstone term loan and the royalty obligations, the Astria acquisition and the acquired in-process research and development charge, the navenibart program, dilution, short interest, sources and FAQ. Available in the Merlintrader Research Library. The report is a dated snapshot and is not updated after that date; this page follows the current situation. For personal use only: redistribution prohibited.
Next catalyst
Third quarter 2027 · navenibart topline in ALPHA-ORBIT
The pivotal study of navenibart, a long-acting plasma kallikrein inhibitor dosed every three and every six months, is fully enrolled, and the company expects top-line results at the six- and twelve-month endpoints in the third quarter of 2027. Before that, initial data in patients with Netherton syndrome from the phase 1 study of BCX17725 are expected by the end of 2026. Third-quarter release, November 4, 2026
Completed: on October 1, 2025 BioCryst sold its European ORLADEYO business. On January 23, 2026 it closed the acquisition of Astria Therapeutics, funded in part by a $400 million term loan from Blackstone. In August 2026 it began shipping ORLADEYO through CareMed as sole-source specialty pharmacy, and in October 2026 the FDA approved the 150 mg oral pellets for patients aged 12 and older. In the September quarter it reported $180.3 million of revenue and $53.3 million of operating profit. Third-quarter release · Form 10-Q
BCRX stock at a glance
Chart analysis · JC
Technical chart analysis of $BCRX with bull and bear scenarios on JC Just Charts.
Total revenue · Q3
$180.3M
Up 13% from $159.4 million; ORLADEYO revenue $174.8 million, and $5.5 million of license and other revenue. Nine months $555.0 million.
Operating profit · Q3
$53.3M
Against $29.6 million; non-GAAP $86.5 million against $50.8 million.
Net loss · nine months
−$605.5M
Driven by $697.8 million of acquired in-process research and development from the Astria acquisition; the quarter alone was a $37.9 million profit.
Cash and investments
$376.4M
At September 30, 2026, after a quarter of positive cash flow.
Term loan · Blackstone
$395.6M
Carrying value of the $400 million facility drawn on January 23, 2026, maturing in 2031, interest only until then.
Guidance · total revenue
$715–730M
Raised from $690–715 million; ORLADEYO held at $625–645 million, non-GAAP operating expense improved to $415–425 million.
Where BioCryst stands now
BioCryst sells one product that pays for the company. ORLADEYO, berotralstat, is an oral once-daily plasma kallikrein inhibitor for hereditary angioedema, a rare genetic condition that causes unpredictable attacks of swelling. In the September quarter it produced $174.8 million of ORLADEYO net revenue and the company as a whole produced $180.3 million, up 13% from a year earlier, and $5.5 million of license and other revenue, with an operating profit of $53.3 million against $29.6 million. The year-over-year comparison is affected by the sale of the European business on October 1, 2025, which is why the company also reports growth of 24% excluding European revenue. Third-quarter release
The quarter’s growth carried an asterisk. In August BioCryst moved ORLADEYO shipments to CareMed as its sole-source specialty pharmacy, and CareMed built an initial inventory of the drug to support patient demand. That build is recognized as revenue to BioCryst, so the reported increase includes a one-time stocking effect that the company says it expects to remain relatively stable rather than to repeat; its own statement is that ORLADEYO revenue excluding European revenue grew when the inventory build is removed. Revenue discussion
Two decisions in 2026 reshaped the balance sheet. The acquisition of Astria Therapeutics, announced in October 2025 and closed on January 23, 2026, brought the long-acting kallikrein inhibitor navenibart and an early atopic dermatitis program, and it was funded with shares and a $400 million term loan from Blackstone. Because the acquired asset had no alternative future use, accounting rules required BioCryst to expense $697.8 million of acquired in-process research and development in the first quarter, which is why nine months show a net loss of $605.5 million and a loss per share of $2.41 while the business excluding that charge generated an operating profit. Form 10-Q, income statement
What the balance sheet says. Total assets were $591.1 million at September 30, 2026 and total liabilities $988.5 million, which leaves stockholders’ deficit of roughly $397 million: the company is solvent in cash terms and negative in book terms, because the accumulated deficit stands at $2.11 billion and the royalty financing obligations at $421.7 million sit alongside the $395.6 million term loan. Cash flow, not book equity, is what carries this company, and the September quarter produced positive cash flow.
▲ The constructive case
ORLADEYO is a growing oral franchise in a disease where patients need a daily prophylaxis, the pellet formulation extends it to children from age 2 and to adolescents and adults from 12, and the company is profitable and generating cash. Full-year ORLADEYO guidance of $625–645 million against $481.4 million of ORLADEYO revenue in the first nine months implies a fourth quarter of $144–164 million (Merlintrader calculation), total revenue guidance was raised to $715–730 million and operating expense guidance was improved to $415–425 million. Navenibart, dosed every three or six months, would be the first injectable in the franchise with a dosing interval that matches the disease; topline is due in the third quarter of 2027 and the program is fully enrolled.
▼ The cautious case
The franchise rests on one product in a market where competitors sell injectables with longer intervals, and the quarter’s growth includes a pharmacy inventory build that the company does not expect to repeat. Nine months carried a $605 million loss and the company has $988.5 million of liabilities against $591.1 million of assets, with $421.7 million of royalty obligations and a $395.6 million term loan that accrued interest at an effective rate of 8.88% in the third quarter, or roughly $8.9 million a quarter on the $400 million principal (Merlintrader calculation). Navenibart’s topline is not due until the third quarter of 2027, and a failure would leave a company that has already spent the acquisition on a program that did not deliver.
Latest BioCryst Pharmaceuticals news
Nov 13, 2026
BioCryst presents real-world evidence of reduced angioedema-related visits after switching to ORLADEYO
BioCryst presented two real-world studies at the ACAAI 2026 Annual Scientific Meeting in Phoenix, Arizona, November 12-16. In a retrospective pre-post study of 78 patients who switched from another long-term prophylactic therapy to ORLADEYO, overall angioedema-related visits decreased significantly by 30% per-patient-year (p=0.039). Angioedema-related outpatient/emergency department visits decreased 30% PPY (p=0.040), while angioedema-related hospitalizations were non-significant (rate ratio 0.54).
Nov 4, 2026
BioCryst to Present at Upcoming Investor Conferences
BioCryst plans to present at the 2026 Jefferies Global Healthcare Conference in London on Wednesday, November 18, 2026. It also plans to present at the 9th Annual Evercore Healthcare Conference in Coral Gables, FL, on Tuesday, December 1, 2026. Live audio webcasts and replays will be available in the Investors & Media section of BioCryst's website at www.biocryst.com.
Nov 4, 2026
BioCryst Reports Third Quarter 2026 Financial Results
BioCryst reported total net revenue of $180.3 million and ORLADEYO net revenue of $174.8 million for the quarter ended September 30, 2026. Operating profit was $53.3 million and Non-GAAP operating profit was $86.5 million. The company maintained its full year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $715 million to $730 million.
Oct 29, 2026
Four ACAAI posters scheduled for November
The November 13–15 posters address ORLADEYO real-world utilization, pediatric dose adjustment and interim ALPHA-SOLAR navenibart findings. This announcement gives a presentation schedule rather than results.
Oct 21, 2026
Q3 results scheduled for November 4
The company schedules results November 4 with a conference call and webcast at 8:30 a.m. Eastern.
Oct 21, 2026
ORLADEYO 150 mg pellets approved for adults and adolescents
The company announced approval of the pellet formulation for prophylaxis in HAE patients aged 12 and older. Formulation approval is distinct from navenibart development or a quantified sales impact.
BCRX stock catalysts: the dated calendar
- October 1, 2025 — European ORLADEYO business sold. Completed · Form 10-Q
- January 23, 2026 — Astria Therapeutics acquisition closed; $400 million Blackstone term loan funded. Completed · Form 10-Q
- August 2026 — ORLADEYO pellets launched for patients aged 2 to under 12; CareMed became sole-source specialty pharmacy. Completed · Company release
- October 2026 — FDA approved the 150 mg oral pellets for patients aged 12 and older. Completed · Company release
- 2026 — STAR-0310, the atopic dermatitis program from Astria, terminated. Completed · Form 10-Q
- By end of 2026 — Initial data in patients with Netherton syndrome from the phase 1 study of BCX17725. Company guidance
- By year-end 2026 — Birmingham site closure substantially complete, with cash costs of about $10 million and annualized savings of $30–35 million. Company guidance
- Third quarter 2027 — Navenibart topline at the six- and twelve-month endpoints of ALPHA-ORBIT. Company guidance
- January 23, 2031 — Maturity of the Blackstone term loan; principal due in one payment. Loan agreement
ORLADEYO: one molecule, three formulations and a payer story
Berotralstat is an oral inhibitor of plasma kallikrein, the enzyme that drives the contact activation system whose uncontrolled activity produces angioedema attacks in people with hereditary angioedema. It is taken once a day, which is its commercial argument: the alternatives are injectable therapies, some of them self-administered at home and some given in a clinic. The capsule reached the market first; the company has added an oral pellet formulation designed for patients who cannot or will not swallow a capsule: the FDA approved it in December 2025 for children aged 2 to under 12, shipments began in August 2026, and in October 2026 the FDA approved the 150 mg pellets for patients aged 12 and older. Product and approvals
The pellet approval matters beyond pediatrics. It converts the product from one presentation into a choice a prescriber can make for a patient at any age, and it addresses the group that has the most difficulty with capsules — young children — where the alternative has often been an injectable administered by a caregiver. The company describes early reimbursement as strong and new prescriptions ahead of its expectations in the pediatric launch, which is a qualitative statement in a quarter when it does not break out pellet revenue. Launch commentary
The franchise also carries the risk of a single product. BioCryst’s revenue is ORLADEYO, its gross margin is ORLADEYO, and its ability to service $421.7 million of royalty obligations and a $400 million term loan is ORLADEYO. That concentration is why navenibart is not a side project: it is the second leg of a business that currently has one.
BioCryst deep dive: the full analysis
The chapters below work through the business in detail: the three scenarios, what would falsify them, the product and the franchise, the pharmacy transition and the inventory effect, the September quarter against the guidance, the navenibart program and the pipeline, the Astria charge and what it did to equity, the debt and royalty structure, dilution, ownership and short interest, and the red flags. The same research is available as a downloadable PDF in the Research Library. The Merlintrader Research Library collects our dated biotech stock research reports.
01 Three scenarios: a cash-generating franchise and a readout due in the third quarter of 2027
Bull case — navenibart works at six-month dosing and ORLADEYO keeps growing
The favorable path has ORLADEYO finishing 2026 inside or above guidance at $625–645 million, the pellet formulation adding a patient segment that capsules could not reach, and navenibart producing topline in the third quarter of 2027 that supports a filing for every three-month and every six-month dosing. A long-acting injectable with a six-month interval would change the franchise from an oral alternative to a portfolio in which the company can offer a patient a choice of route and interval, and it would give BioCryst a second growth product before ORLADEYO’s competition intensifies. Program status
In that scenario the balance sheet stops being a constraint. The company generated positive cash flow in the September quarter while carrying $988.5 million of liabilities, and a growing franchise plus a second product would let it refinance the 2031 maturity from a position of strength or pay it down.
Base case — steady ORLADEYO, spending on navenibart, a readout that decides the next five years
The middle path is the current trajectory extended: ORLADEYO grows modestly as the pellets add patients and the pharmacy transition settles, total revenue lands inside the raised guidance, the Birmingham closure delivers $30–35 million of annualized savings, and the company spends the next four quarters funding ALPHA-ORBIT and the phase 1 work on BCX17725. The readout in the third quarter of 2027 then decides whether BioCryst is a two-product company or a one-product company with an expensive acquisition behind it. Guidance and savings
This path follows what the guidance describes, and the company has already paid for the option: the $697.8 million charge is sunk and the $400 million loan has to be serviced regardless of what the readout shows.
Bear case — the franchise slips before the second product arrives
The adverse path has ORLADEYO decelerating as competitors with longer dosing intervals take share, the pellet launch failing to add enough patients to offset it, and navenibart disappointing in 2027. Revenue would then be flat or falling against $988.5 million of liabilities, $421.7 million of royalty obligations and $21.2 million of interest expense a quarter. BioCryst would have to cut the pipeline, restructure again, or refinance at a worse rate.
The company’s own disclosures identify the dependency: its results depend on ORLADEYO revenue, and a decline in that revenue, whether from competition, pricing or reimbursement, would have a material adverse effect. For a company with one product, that is not a generic sentence.
What would falsify this reading
The reading here is that BioCryst has become a profitable commercial company whose outlook depends on whether the second product arrives before the first one matures. The following would change it.
- ORLADEYO missing the guidance range. Full-year guidance of $625–645 million against $481.4 million of ORLADEYO revenue in the first nine months implies a fourth quarter of $144–164 million; a miss would show that the third quarter’s inventory build was masking slower underlying demand. Source
- A delay in ALPHA-ORBIT. The program is fully enrolled and guided to topline in the third quarter of 2027; any extension of that date pushes the second product past the period in which the current cash flow has to carry the debt. Source
- Competitive pressure on the oral niche. A competitor with a longer dosing interval and a payer position would show up in prescription trends and in the net price the company reports, not in the headline revenue.
- A refinancing on worse terms. The Blackstone loan matures in January 2031; an earlier refinancing at a higher spread, or an amendment with new covenants, would signal that the lenders see the franchise differently from the company.
These are observations that would weaken the interpretation, not forecasts of inevitable events.
02 What BioCryst sells, and what the rest of the pipeline is worth
BioCryst Pharmaceuticals is based in Research Triangle Park, North Carolina, and describes itself as a commercial-stage biotechnology company focused on rare diseases. ORLADEYO is the product; RAPIVAB, an injectable antiviral for influenza, is a small line that contributes to total revenue through international orders; and the rest is pipeline. Charlie Gayer is President and Chief Executive Officer. Company description
The pipeline has three pieces. Navenibart, from Astria, is an injectable monoclonal antibody that inhibits plasma kallikrein with a long half-life, designed for every three-month and every six-month subcutaneous dosing in hereditary angioedema; it is in the pivotal ALPHA-ORBIT study with a long-term extension called ORBIT-EXPANSE. BCX17725 is an inhibitor of kallikrein-5, or KLK5, in a phase 1 study for Netherton syndrome, a severe genetic skin disorder. STAR-0310, the atopic dermatitis antibody also acquired with Astria, was terminated after the company evaluated partnering opportunities for continued development. Form 10-Q, risk factors · Pipeline
The company also formed a scientific advisory board of seven members in October 2026 to guide an external research and development strategy, which is a statement about how it intends to fill the pipeline from outside rather than from its own discovery. Separately, it is winding down its Birmingham, Alabama site, announced in June 2026 and expected to be substantially complete by year-end, with cash costs of about $10 million and annualized savings of $30–35 million once fully realized. Restructuring
03 The pharmacy transition and the inventory that flattered the quarter
In August 2026 BioCryst moved ORLADEYO shipments to CareMed as its sole-source specialty pharmacy partner, replacing its previous specialty pharmacy. The company’s reasoning is that a single partner with rare-disease experience and high-touch patient services drives better adherence and growth; the accounting consequence is that the partner built an initial inventory to support patient demand and efficient dispensing, and BioCryst recognized that build as revenue in the third quarter. Pharmacy transition
The company expects the inventory level to remain relatively stable over time, so the initial build should not repeat, and it states that ORLADEYO revenue excluding European revenue grew year over year when the effect of the initial build is removed. That is the correct way to read the quarter — the underlying demand grew, and the reported growth of 13% includes a stocking benefit that is a one-time transfer of inventory onto a partner’s balance sheet. Revenue discussion
The transition also added cost. Sales and marketing expense was $37.7 million excluding share-based compensation, down 15% year over year, and $36.0 million on a non-GAAP basis, up 4%, with fees related to the specialty pharmacy transition contributing to the increase. Fees paid once to move a distribution channel are exactly the kind of cost that does not recur, and they are also the kind that shows up in the quarter when the stocking benefit does. Expense detail
For a reader, the practical test is the fourth quarter. If the inventory level stays stable, fourth-quarter ORLADEYO revenue should reflect demand rather than stocking, and the comparison with the third quarter will be the cleanest read on the franchise’s growth rate that the year offers.
04 The September quarter against the guidance
| Line item ($ thousands) | Q3 2026 | Q3 2025 | 9M 2026 | 9M 2025 |
|---|---|---|---|---|
| Product sales, net | 172,295 | 157,735 | 481,209 | 463,952 |
| License and other revenue | 7,997 | 1,660 | 73,746 | 4,330 |
| Total revenues | 180,292 | 159,395 | 554,955 | 468,282 |
| Acquired in-process research and development | — | — | 697,761 | — |
| Research and development | 58,213 | 44,603 | 170,501 | 125,259 |
| Selling, general and administrative | 67,175 | 83,014 | 225,705 | 252,866 |
| Income (loss) from operations | 53,330 | 29,591 | (549,803) | 80,604 |
| Interest expense | 21,185 | 19,661 | 62,676 | 64,737 |
| Net income (loss) | 37,916 | 12,899 | (605,501) | 18,016 |
| Diluted earnings (loss) per share | 0.14 | 0.06 | (2.41) | 0.08 |
Total revenue rose 13% to $180.3 million; research and development expense rose to $58.2 million from $44.6 million, including $6.3 million of cash restructuring costs and $9.3 million of non-cash impairment and termination charges related to the Birmingham closure, and $52.4 million excluding share-based compensation. Selling, general and administrative expense fell to $67.2 million from $83.0 million, because the $12.1 million of European business expenses of a year earlier were gone and share-based compensation and general and administrative spending were lower. The result was income from operations of $53.3 million against $29.6 million, and net income of $37.9 million against $12.9 million. Quarterly results
The nine-month picture is dominated by the acquisition. Revenue of $555.0 million includes $73.7 million of license and other revenue, largely from the licensing of European navenibart rights; the $697.8 million of acquired in-process research and development turns an operating business into a $605.5 million loss. Interest expense of $62.7 million for nine months reflects the royalty financing obligations and, from January, the Blackstone term loan. Income statement
The guidance is the part that carries information about the fourth quarter. BioCryst held ORLADEYO at $625–645 million for the full year, which against $481.4 million of ORLADEYO revenue in the first nine months implies a fourth quarter of $144–164 million; total revenue guidance rose to $715–730 million from $690–715 million, on higher navenibart licensing revenue and higher RAPIVAB orders; and non-GAAP operating expense guidance improved to $415–425 million from $420–440 million on the progress of the site closure. Guidance table
05 Navenibart and the pipeline: the second leg
Navenibart is an injectable monoclonal antibody that inhibits plasma kallikrein and is engineered for a long duration of action, which is why BioCryst studies it at every three months and every six months rather than at the two- or four-week intervals of some injectable HAE therapies. The pivotal study, ALPHA-ORBIT, is fully enrolled and is running with a long-term extension, ORBIT-EXPANSE; top-line results at the six- and twelve-month endpoints are guided to the third quarter of 2027. Program status
The commercial logic is a trade of route for interval. ORLADEYO is oral and daily; navenibart would be subcutaneous and twice or four times a year. Some patients prefer a pill and some prefer an injection they barely think about, and the two can be sold to the same physician base and through the same rare-disease infrastructure. If the readout supports both intervals, BioCryst would be able to offer a six-month dosing option, which is the basis of the case for having paid $874.3 million for Astria, funded partly with $400 million of debt. Acquisition rationale
BCX17725 is the earlier bet. It inhibits KLK5, an enzyme implicated in Netherton syndrome, a rare, lifelong genetic skin disorder for which no approved treatment targets the underlying cause. The phase 1 study has enrolled Part 4 and the company expects initial data in patients by the end of 2026. A positive signal in a disease with no approved treatment of its underlying cause would be a valuable asset; a negative one costs little beyond the spend already committed. BCX17725 status
The STAR-0310 decision is worth noting as a signal of capital discipline. BioCryst evaluated partnering opportunities for the atopic dermatitis program and then determined to terminate it, to focus the pipeline on rare diseases. The program cost $0.8 million in research and development in the first half of 2026, a small amount against the alternative of carrying a dermatology program through a company that has just committed itself to rare disease and to a 2027 readout.
06 The Astria charge and why equity is negative
The acquisition of Astria Therapeutics was structured as a merger announced on October 14, 2025 and closed on January 23, 2026, with Astria surviving as a wholly owned subsidiary of BioCryst. The consideration was $608.6 million in cash and $251.7 million in stock, plus $14.0 million of transaction costs, and the cash portion was funded in part with the $400 million term loan. Under generally accepted accounting principles, an acquired research and development asset with no alternative future use is expensed immediately rather than capitalized, so the $697.8 million attributed to navenibart went through the income statement in the first quarter of 2026. Business combination note
The consequence is a balance sheet that looks worse than the business. The deficit is the accumulated record of expensed research over two decades plus this acquisition, and most of the liabilities are long-dated: $792.6 million of the $988.5 million is non-current (Merlintrader calculation).
For a reader the practical point is that book value is not the measure to use on this company. Cash flow from the franchise, the interest cost of the debt and the timing of the 2031 maturity are. A company with negative book equity and positive operating cash flow is the result here of an acquired asset being expensed rather than capitalized.
07 Debt, royalties and the cost of the acquisition
BioCryst carries two large financing structures. The first is a set of royalty financing obligations of $421.7 million, of which $43.7 million is current, incurred in earlier transactions in which the company sold a share of future ORLADEYO royalties for cash. The second is the Blackstone loan agreement of January 23, 2026: $400 million of term loans, a carrying value of $395.6 million at September 30, 2026, maturing on January 23, 2031, with quarterly interest-only payments and principal due at maturity. Interest accrues at three-month Secured Overnight Financing Rate, with a floor of 1.75%, plus 4.50% a year, and the company may request up to $150 million of additional term loans by mutual agreement. Debt note
Interest expense was $21.2 million in the quarter and $62.7 million in nine months. Against income from operations of $53.3 million, that leaves $32.1 million after interest expense and before interest income and other items (Merlintrader calculation); income before income taxes was $38.6 million. The royalty obligations are the reason the interest line is high relative to the debt: a royalty financing repays through a percentage of revenue rather than through a fixed schedule, so the reported interest includes the imputed cost of those arrangements. Interest expense
The 2031 maturity is the long-term refinancing question. BioCryst has about four years to grow the franchise, to bring navenibart to market and to arrive at that date with either the cash to repay or the revenue to refinance on better terms. The $150 million accordion is available only by mutual agreement, which means the lenders hold the option rather than the company.
08 Dilution: 213 million to 257 million shares
Shares outstanding were 213,060,000 at December 31, 2025, 256,118,000 at September 30, 2026 and 257,299,269 at October 30, 2026, against 450 million authorized. The increase is largely the stock component of the Astria consideration, and it is the reason the weighted average count rose from 209.5 million in the first nine months of 2025 to 250.8 million in the same period of 2026. Share count
The dilution has an offset that most small biotechs do not have: the company is now profitable and generating cash. Diluted earnings per share of $0.14 in the quarter used 267.6 million diluted shares against basic 255.6 million, which means the dilutive securities are in the money and the earnings are already shared with them. A company that earns its way through dilution is a different proposition from one that issues shares to fund a loss.
The remaining overhang is the equity compensation and the shares reserved under the company’s plans, plus whatever is issued if the term loan accordion is drawn or a future acquisition uses stock. The company’s financing in 2026 was the loan and the merger consideration rather than continuous selling into the market. Capital structure
09 Ownership, short interest and liquidity
Two Schedule 13G filings arrived in November 2026, and neither shows a holder above 5%. On November 10, State Street Corporation reported 12,294,412 shares, or 4.8% of the class, as of September 30, 2026. On November 16, RA Capital Management, L.P. and the other reporting persons filed Amendment No. 2 reporting no shares beneficially owned, 0.0%, as of September 30, 2026. Schedule 13G filings
Short interest is meaningful but not extreme. At the October 30, 2026 settlement date, 27,637,852 shares were short, equal to 5.09 days of average volume of 5,429,684 shares, or roughly 10.7% of the 257.3 million shares outstanding; at October 15 it was 26,597,263 shares and 5.81 days. The position is stable and it is large enough that a positive navenibart readout would produce covering, and small enough that it does not by itself indicate a thesis against the company. Nasdaq short-interest table, settlement October 30, 2026
Liquidity is unusually good for a company of this size: average daily volume above five million shares, and a business that generates cash. Trading depth of that kind is a practical benefit of having become a commercial company.
10 Red flags, the next operating test and the assessment
The first red flag is concentration. One product produces almost all of the revenue, secures the royalty obligations and services the term loan, and the second product does not read out until the third quarter of 2027.
The second is the quality of the third-quarter growth. The CareMed inventory build is a one-time benefit that the company expects to remain stable rather than repeat, and the fourth quarter is the first clean comparison.
The third is the balance sheet in book terms. Liabilities of $988.5 million against assets of $591.1 million, an accumulated deficit of $2.11 billion and $421.7 million of royalty obligations mean the company has little room for a revenue disappointment before the debt becomes the conversation.
The fourth is the interest burden. $21.2 million of interest expense in the quarter absorbs about 40% of the $53.3 million of income from operations (Merlintrader calculation), so a revenue shortfall would reach profit quickly once financing costs are included.
The fifth is the pipeline’s record. STAR-0310 was discontinued, the Birmingham site is closing, and the strategy now relies on external research guided by a newly formed advisory board, which is a reasonable approach and also an admission that internal discovery has not produced a second product.
The next operating test is the fourth quarter: ORLADEYO revenue without a stocking benefit, the pellet contribution, and the operating expense trajectory against the improved guidance. The decisive test is the navenibart topline in the third quarter of 2027, which is the event the acquisition was made for.
BioCryst has crossed from a company that funds a pipeline with equity to one that funds it with product cash flow, and the Astria acquisition was the moment it chose to spend that cash flow in advance. The franchise is real, the profit is real, and the debt is real; the next two years are about whether the second product arrives before the first one has to carry the whole structure alone.
Merlintrader Health Score · $BCRX
3.65out of 5
Assessed on November 18, 2026, on the quarter ended September 30, 2026. Weighted calculation: 4.0×30% + 3.0×30% + 3.5×20% + 4.0×10% + 4.5×10% = 1.20 + 0.90 + 0.70 + 0.40 + 0.45 = 3.65. The score describes financial and operational robustness over twelve to eighteen months. It is not a rating, a target price or an indication to buy or sell.
Red flags
- Almost all revenue and all debt service depend on a single product, ORLADEYO.
- Third-quarter growth includes a one-time specialty pharmacy inventory build that the company expects to remain stable rather than repeat.
- Total liabilities of $988.5 million against total assets of $591.1 million, with stockholders’ deficit of roughly $397 million.
- The nine months to September 30 show a net loss of $605.5 million, driven by $697.8 million of acquired in-process research and development.
- $421.7 million of royalty financing obligations and a $395.6 million term loan, with interest expense of $62.7 million in nine months.
- The $400 million term loan matures on January 23, 2031, with principal due in one payment and only $150 million of further capacity by mutual agreement.
- The second product, navenibart, does not report topline until the third quarter of 2027.
- STAR-0310 was terminated after partnering opportunities were evaluated, and the strategy now relies on external research.
- The Birmingham closure carries about $10 million of cash costs and its savings of $30–35 million are annualized only once fully realized.
- Pricing, reimbursement and competition in hereditary angioedema determine the franchise, and the company does not control any of the three.
BCRX Stock FAQ: BioCryst Questions Answered
When is the next BCRX stock catalyst?
Navenibart topline at the six- and twelve-month endpoints of the pivotal ALPHA-ORBIT study is guided to the third quarter of 2027, and initial data in patients with Netherton syndrome from the phase 1 study of BCX17725 are expected by the end of 2026. Details.
How much revenue does BioCryst make?
Total revenue was $180.3 million in the quarter ended September 30, 2026, of which ORLADEYO contributed $174.8 million. Nine-month total revenue was $555.0 million. Full-year guidance is $625–645 million for ORLADEYO and $715–730 million in total. Details.
Is BioCryst profitable?
Yes at the operating level: operating profit was $53.3 million in the September quarter against $29.6 million a year earlier, and net income was $37.9 million. The nine-month net loss of $605.5 million comes from $697.8 million of acquired in-process research and development expensed on the Astria acquisition. Details.
How much cash does BioCryst have?
Cash, cash equivalents, restricted cash and investments totaled $376.4 million at September 30, 2026, after the company generated positive cash flow in the quarter. Details.
How much debt does BioCryst carry?
A $400 million secured term loan from Blackstone, drawn on January 23, 2026 and carried at $395.6 million at September 30, 2026, maturing on January 23, 2031, interest only until maturity, plus $421.7 million of royalty financing obligations. Details.
Is BCRX at risk of dilution?
The share count rose from 213,060,000 at December 31, 2025 to 257,299,269 at October 30, 2026, largely through the stock consideration for Astria Therapeutics, against 450 million authorized. With the company now profitable, further dilution would most likely come from acquisitions or equity compensation rather than from funding operating losses. Details.
What is ORLADEYO and what changed in 2026?
ORLADEYO, berotralstat, is an oral once-daily plasma kallikrein inhibitor for hereditary angioedema. In 2026 BioCryst began shipping its oral pellet formulation for children aged 2 to under 12 in August and received FDA approval in October for the 150 mg pellets for patients aged 12 and older, and it moved to CareMed as sole-source specialty pharmacy. Details.
Primary sources
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $BCRX or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company releases, regulatory correspondence as described in those filings and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.
Commercial-stage biotechnology companies carry concentration, financing and reimbursement risk. A single-product company can lose revenue faster than it can replace it, a term loan with principal due at maturity has to be repaid or refinanced, and a royalty financing obligation is paid out of the same revenue that services everything else. BioCryst reported operating profit of $53.3 million in the September quarter, a $605.5 million net loss for nine months, $376.4 million of cash and investments and $988.5 million of liabilities against $591.1 million of assets. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



